TCR-MHC/peptide interaction: prospects for new anti-tumoral agents.
Cancer Genomics Proteomics
; 11(6): 267-77, 2014.
Article
em En
| MEDLINE
| ID: mdl-25422358
ABSTRACT
Tumor-related antigens can be presented as peptides forming complexes with major histocompatibility complex (MHC) molecules that interact with T-cell receptors, thus generating an immunologic anti-tumor response. Unfortunately, however, this response can be decreased by many effectors and pathways. On the other hand, such peptide-MHC complexes are unique starting points for therapeutic intervention. We present strategies for eliciting an anti-tumoral response by T-cell receptor-based fusion proteins with interleukin (IL)2 and antibody constant region domains, superantigens, and T-cell recruiting antibodies, as well as using genetically modified autologous T-cells as effectors. Another strategy is to direct peptide-MHC complexes to tumors as fusion proteins with an antibody-derived targeting moiety. Finally, we describe T-cell receptor-mimicking antibodies and antibody conjugates as anti tumoral agents.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Receptores de Antígenos de Linfócitos T
/
Antígenos de Histocompatibilidade
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Genomics Proteomics
Assunto da revista:
BIOQUIMICA
/
GENETICA MEDICA
/
NEOPLASIAS
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Alemanha